Document Detail

Management of Myeloma: Current and Future Approaches.
MedLine Citation:
PMID:  10761055     Owner:  NLM     Status:  Publisher    
BACKGROUND: The treatment of multiple myeloma, relatively stagnant for many years, appears to be entering a promising era for improvement. This paper reviews treatment interventions available for patients with multiple myeloma to indicate a standard approach and to evaluate the spectrum of current standard therapy. METHODS: The author reviews published literature on the treatment of multiple myeloma. Both journal articles and papers presented at national and international meetings are utilized. RESULTS: Intensive combination chemotherapy offers relatively modest improvement over standard melphalan plus prednisone, but the use of interferon for maintenance therapy lengthens response duration and possibly survival. High-dose chemotherapy with stem-cell transplantation is a relatively safe and effective treatment modality for patients under 70 years of age at first relapse. Studies in progress will determine its role in first response consolidation. Use of hematopoietic growth factors, prophylactic antibiotics, and bisphosphonate treatment of lytic bone disease has diminished disease morbidity. CONCLUSIONS: While cure of multiple myeloma remains elusive and 10-year survival is still uncommon, newer treatment approaches offer better control of disease manifestations and perhaps a real opportunity to prolong functional life. Future treatments that will address minimal residual disease may improve long-term survival.
Related Documents :
3339395 - Emergency laparotomy for spontaneous intestinal and colonic perforations in cancer pati...
16019485 - Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed,...
3753645 - Successful treatment of meningeal myeloma with combination of radiation therapy, chemot...
12504655 - Response to first-line chemotherapy and long-term survival in patients with multiple my...
9137495 - High-dose tamoxifen reverses drug resistance to cisplatin and etoposide in a patient wi...
23104465 - Cabozantinib for the treatment of advanced medullary thyroid cancer.
Publication Detail:
Journal Detail:
Title:  Cancer control : journal of the Moffitt Cancer Center     Volume:  5     ISSN:  1526-2359     ISO Abbreviation:  Cancer Control     Publication Date:  1998 May 
Date Detail:
Created Date:  2000-04-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9438457     Medline TA:  Cancer Control     Country:  -    
Other Details:
Languages:  ENG     Pagination:  218-225     Citation Subset:  -    
Virginia Piper Cancer Institute, Northwestern Hospital, Minneapolis, Minnesota 55407-3799, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Biology of the Transition of Monoclonal Gammopathy of Undetermined Significance (MGUS) to Multiple M...
Next Document:  Interferon in the Treatment of Multiple Myeloma.